Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

completed250%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
unknownnot_applicable

WHOle Brain Irradiation or STEreotactic Radiosurgery for Five or More Brain Metastases (WHOBI-STER)

NCT04891471
completed

MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier

NCT01988675
unknownnot_applicable

Sector Irradiation Versus Whole Brain Irradiation for Brain Metastasis

NCT01667640
completedphase_2

Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment

NCT01015534

Clinical Trials (4)

Showing 4 of 4 trials
NCT04891471Not Applicable

WHOle Brain Irradiation or STEreotactic Radiosurgery for Five or More Brain Metastases (WHOBI-STER)

Unknown
NCT01988675

MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier

Completed
NCT01667640Not Applicable

Sector Irradiation Versus Whole Brain Irradiation for Brain Metastasis

Unknown
NCT01015534Phase 2

Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment

Completed

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4